On 14 December 2018, orphan designation (EU/3/18/2113) was granted by the European Commission to MUCPharm Pty Ltd, United Kingdom, for bromelain for the treatment of pseudomyxoma peritonei.
The sponsorship was transferred to Mucpharm Europe Limited in February 2020.
|Disease / condition||
Treatment of pseudomyxoma peritonei
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.